Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy.

[1]  An Na Seo,et al.  HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. , 2014, American journal of clinical pathology.

[2]  C. Gilks,et al.  Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Tae Oh Kim,et al.  Intratumoral heterogeneity impacts the response to anti-neu antibody therapy , 2014, BMC Cancer.

[4]  E. Perez,et al.  Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study , 2014, Breast Cancer Research and Treatment.

[5]  M. Hidalgo,et al.  Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Jong-Hyeon Jeong,et al.  Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. , 2013, Journal of the National Cancer Institute.

[7]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Dowsett,et al.  HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  M. Dowsett,et al.  2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial , 2013, The Lancet.

[10]  S. Im,et al.  HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer , 2013, Cancer Chemotherapy and Pharmacology.

[11]  E. Perez,et al.  Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005) , 2013, Breast Cancer Research and Treatment.

[12]  P. Fasching,et al.  HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer , 2013, Breast Cancer Research.

[13]  N. Moatamed,et al.  High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines , 2012, Modern Pathology.

[14]  Eunyoung Kang,et al.  Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance , 2012, Modern Pathology.

[15]  M. Tibiletti,et al.  Genetic heterogeneity in HER2 testing may influence therapy eligibility , 2012, Breast Cancer Research and Treatment.

[16]  Dafydd G. Thomas,et al.  HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. , 2012, Cancer research.

[17]  J. Bartlett,et al.  HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. , 2012, American journal of clinical pathology.

[18]  H. Moch,et al.  Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer , 2012, Breast Cancer Research and Treatment.

[19]  Janet I. Malowany,et al.  ‘Genetic heterogeneity’ in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases , 2012, Modern Pathology.

[20]  L. Goldstein,et al.  Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Marc Buyse,et al.  Adjuvant trastuzumab in HER2-positive breast cancer. , 2011, The New England journal of medicine.

[22]  Jong-Hyeon Jeong,et al.  Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. J. van de Vijver,et al.  HER2 gene amplification in patients with breast cancer with equivocal IHC results , 2011, Journal of Clinical Pathology.

[24]  Alastair I. Bartlett,et al.  Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. , 2011, American journal of clinical pathology.

[25]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Weidong Huang,et al.  Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization‐positive patients with metastatic breast cancer treated with trastuzumab , 2010, Cancer.

[27]  E. Perez,et al.  HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  K. Allison,et al.  Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. , 2010, American journal of clinical pathology.

[29]  Peter A Fasching,et al.  Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Petropoulos,et al.  Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer , 2010, BMC Cancer.

[31]  M. Arbushites,et al.  Chromosome 17 Polysomy without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared with Paclitaxel in Metastatic Breast Cancer , 2010, Clinical Cancer Research.

[32]  P. Diest,et al.  Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification , 2010, Breast Cancer Research and Treatment.

[33]  Raymond R Tubbs,et al.  Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. , 2009, Archives of pathology & laboratory medicine.

[34]  A. Ashworth,et al.  Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis , 2009, The Journal of pathology.

[35]  David G. Hicks,et al.  HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. , 2009, The oncologist.

[36]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[37]  John M S Bartlett,et al.  Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Sotiriou,et al.  Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[39]  M. Arbushites,et al.  HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer , 2008, Clinical Cancer Research.

[40]  Patrick Neven,et al.  Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S. Paik,et al.  HER2 status and benefit from adjuvant trastuzumab in breast cancer. , 2008, The New England journal of medicine.

[42]  I. Christensen,et al.  Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002–2006. A nationwide study including correlation between HER-2 status and other prognostic variables , 2008, Acta oncologica.

[43]  M. Ellis,et al.  CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC) , 2007 .

[44]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[45]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[46]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[47]  M. Press,et al.  Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab , 2005, Breast Cancer Research and Treatment.

[48]  C. Vogel,et al.  Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. , 2005, Clinical breast cancer.

[49]  L. Goldstein,et al.  HER-2 testing in breast cancer using parallel tissue-based methods. , 2004, JAMA.

[50]  M. Dowsett,et al.  Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres , 2003, The Journal of pathology.

[51]  Greg Yothers,et al.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.

[52]  Peter A Kaufman,et al.  Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. , 2002, Journal of the National Cancer Institute.

[53]  Yosef Yarden,et al.  Biology of HER2 and Its Importance in Breast Cancer , 2001, Oncology.

[54]  T. Grogan,et al.  Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[56]  A. Gown,et al.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  D. Slamon,et al.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.

[59]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[60]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[61]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[62]  C R King,et al.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.

[63]  Dequan Liu,et al.  Impact of polysomy 17 on HER2 testing of invasive breast cancer patients. , 2014, International journal of clinical and experimental pathology.

[64]  D. Dabbs,et al.  Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases. , 2014, American journal of clinical pathology.

[65]  Mitch Dowsett,et al.  HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity , 2014, Modern Pathology.

[66]  G. Kroemer,et al.  Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management. , 2013, Cancer genetics.

[67]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[68]  N. Collins,et al.  A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. , 2011, American journal of clinical pathology.

[69]  Z. Gatalica,et al.  Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17 , 2011, Cancer.

[70]  G. Hortobagyi,et al.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  J. Bartlett,et al.  Chromosome 17 Aneusomy is Associated with Poor Prognostic Factors in Invasive Breast Carcinoma , 2004, Breast Cancer Research and Treatment.